BMI MD - Tirzepatide

New patients complete an online health questionnaire covering medical history and weight-loss goals, then typically receive a same-day telehealth consultation with a board-certified physician who determines eligibility. If approved, medication and supplies ship directly from a US-based licensed partner pharmacy.

Take the free 2-minute quiz now & see if you qualify

bmiMD describes compounded tirzepatide as a dual GLP-1/GIP agonist that “act[s] on areas in the brain that regulate appetite while also improving how your body processes sugar and fat.” The site’s marketing page features individual patient testimonials citing specific weight-loss figures, alongside a disclaimer that “results may vary and depend on individual adherence, provider guidance, and lifestyle changes.”

Beyond tirzepatide, bmiMD offers compounded semaglutide and several other telehealth wellness programs, including sermorelin, NAD+, glutathione, and supporting medications like metformin and MIC + B12 injections, none of which are covered in this Tirzepatide-focused review.

These testimonials are taken directly from our partners’ website. We make no warranties regarding the efficiency of the product. Results may vary per patient.

Take the free 2-minute quiz now & see if you qualify

The entire process is online, starting with a short health quiz, with no in-person visit required per bmiMD. Members manage their subscription, refills, and messaging through an online patient portal.

bmiMD advertises “24/7 clinician access, 100% online,” including unlimited messaging with a provider to discuss side effects and dosage adjustments, plus monthly physician check-ins and a customer service team for medication management and refills.

bmiMD states its compounded medications are “produced in FDA-registered facilities but are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality.” The company describes third-party testing for potency (within ±10% of target strength), sterility (per USP 797), pH balance, and endotoxin levels (per USP 85). Common side effects associated with GLP-1/GIP medications include nausea, vomiting, diarrhea, constipation, abdominal pain, and decreased appetite, with more serious risks including pancreatitis, kidney problems, and gallbladder disease disclosed on bmiMD’s safety page.